MedTrace Logo

Modafinil - Escitalopram Study for Cocaine Dependence

NCT01601730 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2012-05-18

No results posted yet for this study

Summary

The purpose of this study is to improve the efficacy of modafinil as a potential treatment for cocaine dependence.

Conditions

Interventions

DRUG

Modafinil and Escitalopram

Treatment 4: Modafinil 200 mg + Escitalopram 20 mg

DRUG

Placebo

Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).

DRUG

Modafinil

Treatment 2: Modafinil 200 mg + Escitalopram 0.

DRUG

Escitalopram

Treatment 3: Modafinil 0 + Escitalopram 20 mg.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Richard De La Garza, Ph.D. · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601730 on ClinicalTrials.gov